Sainis K B, Gadgil M B, Phondke G P
Immunopharmacology. 1984 Oct;8(2):61-8. doi: 10.1016/0162-3109(84)90044-4.
The antischistosomal drug niridazole has been shown to inhibit inductive (Vadas and Bernard, 1981) as well as effector phases of delayed hypersensitivity (Sainis et al., 1983). Furthermore, it also abrogates help for delayed hypersensitivity in antigen-primed animals (Sainis et al., 1983). The effect of this drug on antigen-induced suppression was examined in the present studies. Profound suppression of delayed hypersensitivity to sheep erythrocytes was obtained in Wistar rats given 10(8) erythrocytes (i.v.) 6 days before the immunizing dose (2 x 10(9) erythrocytes, i.p.). When these rats were orally administered niridazole (50 mg/kg) 7 days before the tolerising dose of antigen, suppression of delayed hypersensitivity was not obtained. Splenic lymphocytes of rats given the tolerising dose 6 days earlier adoptively transferred the suppression to inbred recipients. Treatment of these afferent suppressor cells with sera from niridazole-treated unimmunized rats abrogated their function. Likewise, the efferent suppressor cells obtained from fully tolerised rats did not suppress the delayed hypersensitivity when co-transferred with immune lymphocytes, if they were pretreated with niridazole-active serum. The metabolite of niridazole present in this serum seems to impair the suppressor cells functionally. Niridazole may thus prove to be a versatile immunomodulator for effector, helper and suppressor T-cells.
抗血吸虫药硝唑咪已被证明能抑制迟发型超敏反应的诱导期（瓦达斯和伯纳德，1981年）以及效应期（萨尼斯等人，1983年）。此外，它还能消除抗原致敏动物中对迟发型超敏反应的辅助作用（萨尼斯等人，1983年）。本研究检测了该药对抗原诱导抑制作用的影响。在免疫剂量（2×10⁹个红细胞，腹腔注射）前6天静脉注射10⁸个红细胞的Wistar大鼠中，对绵羊红细胞的迟发型超敏反应得到了显著抑制。当这些大鼠在给予耐受剂量抗原前7天口服硝唑咪（50毫克/千克）时，未获得迟发型超敏反应的抑制效果。6天前给予耐受剂量的大鼠的脾淋巴细胞将这种抑制作用过继转移给近交系受体。用硝唑咪处理过的未免疫大鼠的血清处理这些传入抑制细胞可消除其功能。同样，如果用硝唑咪活性血清预处理，从完全耐受的大鼠获得的传出抑制细胞在与免疫淋巴细胞共转移时不会抑制迟发型超敏反应。该血清中存在的硝唑咪代谢产物似乎在功能上损害了抑制细胞。因此，硝唑咪可能被证明是一种对效应性、辅助性和抑制性T细胞具有多种作用的免疫调节剂。
